Celadon Pharmaceuticals PLC
LSE:CEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (0.3), the stock would be worth GBX16.06 (20% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | GBX13.4 |
0%
|
| 3-Year Average | 0.3 | GBX16.06 |
+20%
|
| 5-Year Average | 77.6 | GBX4 219.86 |
+31 391%
|
| Industry Average | 0.1 | GBX6.04 |
-55%
|
| Country Average | 0 | GBX1.14 |
-91%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
C
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
9.2m GBP | 0.2 | -0 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
292.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 351.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.8B ZAR | 5.6 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.3B USD | 0 | 38 034.1 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
53B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.1B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 1.1 | 175.7 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
34.4B USD | 14.3 | -3 142.4 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.6B ZAR | 5.6 | 6.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 767.5 |
Other Multiples
Celadon Pharmaceuticals PLC
Glance View
Summerway Capital Plc engages in acquiring companies or businesses that has the potential for strategic, operational, and performance improvement. The firm is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The firm is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The company is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. The firm's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The firm's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
